The purposes of this study are to identify possible genes that may increase the risk of aneurysm development in the brain, and to determine the effect of environmental factors such as cigarette smoking and high blood pressure on the expression of these genes.

Condition
Intracranial Aneurysm Subarachnoid Hemorrhage

Further Study Details: 

Expected Total Enrollment:  3800

Intracranial aneurysms are “blisters” which form within the arteries at the base of the brain. A rupture of an aneurysm may lead to subarachnoid hemorrhage (SAH). The mortality rates of patients suffering from a SAH is 40 to 44 percent , with many survivors enduring major disability. Most of the deaths from SAH are due to rapid and massive brain injury from the initial bleeding, which is not correctable by medical and surgical intervention. Thus, prevention of aneurysm formation is of paramount importance.

Scientific evidence suggests that a genetic component plays an important role in the development of intracranial aneurysms, however the specific genes have not been identified. The Familial Intracranial Aneurysm Study is a collaborative research effort of neurologists and neurosurgeons throughout the United States, Canada, Australia and New Zealand to identify possible genes that may increase the risk of stroke, and particularly, the development of aneurysms in the blood vessels of the brain. This study will involve 475 families with multiple affected family members, and will also determine the effect of environmental factors such as cigarette smoking and high blood pressure on the expression of the genes.

The identification of susceptibility genes, along with a better understanding of environmental interactions such as cigarette smoking, may result in preventing the development of intracranial aneurysms and/or intracranial aneurysm ruptures in people who are at risk for this condition.

Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Accepts Healthy Volunteers

Criteria

Inclusion:

• To be eligible to participate in this study, families must have two or more affected pairs of siblings (brothers/sisters) or 3 or more family members affected with intracerebral aneurysms.

Exclusion:

• A history of polycystic kidney disease, Marfan's Syndrome, Ehlers Danlos Syndrome, or fibromuscular dysplasia.

Laura Sauerbeck, RN, BSN, MS, CCRC      800-503-3427    laura.sauerbeck@uc.edu

Alabama
      University of Alabama, Birmingham,  Alabama,  United States; Recruiting
California
      Stanford University Medical Center, Stanford,  California,  United States; Recruiting
      University of California,, San Francisco,  California,  94143-0114,  United States; Recruiting
      USC Medical Center, Neurological Surgery, Los Angeles,  California,  90033,  United States; Recruiting
Florida
      University of Florida, Gainesville,  Florida,  32610-0265,  United States; Recruiting
Illinois
      Northwestern Memorial, Northwestern University, Chicago,  Illinois,  United States; Recruiting
Indiana
      Indianapolis Neurosurgical Group, Indianapolis,  Indiana,  United States; Recruiting
Maryland
      University of Maryland, Baltimore,  Maryland,  21201-1595,  United States; Recruiting
      Johns Hopkins University School of Medicine, Baltimore,  Maryland,  21287,  United States; Recruiting
Massachusetts
      Massachusetts General Hospital, Boston,  Massachusetts,  02114-2698,  United States; Recruiting
      Brigham & Women's Hospital, Boston,  Massachusetts,  02115,  United States; Recruiting
Michigan
      University of Michigan, Ann Arbor,  Michigan,  48109-0489,  United States; Recruiting
Minnesota
      Mayo Clinic, Rochester,  Minnesota,  55905,  United States; Recruiting
Missouri
      Washington University, St. Louis,  Missouri,  63110,  United States; Recruiting
New Jersey
      UMDNJ, Newark,  New Jersey,  United States; Recruiting
New York
      Columbia University,, New York,  New York,  10032,  United States; Recruiting
Ohio
      University of Cincinnati, Department of Neurology, Cincinnati,  Ohio,  45267,  United States; Recruiting
      Cleveland Clinic Foundation, Cleveland,  Ohio,  44195,  United States; Recruiting
Pennsylvania
      University of Pittsburgh,, Pittsburgh,  Pennsylvania,  15213,  United States; Recruiting
Texas
      University of Texas at Houston, Houston,  Texas,  77030,  United States; Recruiting
Virginia
      University of Virginia, Charlottesville,  Virginia,  22903,  United States; Recruiting
Washington
      University of Washington, Seattle,  Washington,  98104,  United States; Recruiting
Australia
      Royal Melbourne Hospital, Parkville,  Australia; Recruiting
      Royal North Shore, Sydney,  Australia; Recruiting
Australia, New South Wales
      Royal North Shore Hospital, St. Leonards,  New South Wales,  Australia; Recruiting
      Westmead Hospital, Westmead,  New South Wales,  Australia; Recruiting
      Royal Prince Alfred Hospital, Camperdown,  New South Wales,  Australia; Recruiting
Australia, Victoria
      Alfred Hospital, Prahran,  Victoria,  Australia; Recruiting
Australia, Western Australia
      Royal Perth Hospital, Perth,  Western Australia,  Australia; Recruiting
      Sir Charles Gairdner Hospital, Nedlands,  Western Australia,  Australia; Recruiting
Canada
      University of Ottawa, Ontario,  K1H 8L6,  Canada; Recruiting
Canada, Manitoba
      St. Boniface General Hospital, University of Winnepeg, Winnipeg,  Manitoba,  R2H 2A6,  Canada; Recruiting
Canada, Ontario
      University of Western Ontario, London Health Sciences Center, London,  Ontario,  N6A 5A5,  Canada; Recruiting
Canada, Quebec
      CHUM Notre Dame Hospital, Center for the Study of Brain Disease, Montreal,  Quebec,  H3G 1A4,  Canada; Recruiting
New Zealand
      University of Auckland, Clinical Trials Research Unit, Auckland,  New Zealand; Recruiting

Study chairs or principal investigators

Joseph P. Broderick, M.D.,  Principal Investigator,  University of Cincinnati   

Study ID Numbers:  R01NS39512
Record last reviewed:  March 2005
Last Updated:  March 29, 2005
Record first received:  October 28, 2003
ClinicalTrials.gov Identifier:  NCT00071565
Health Authority: United States: Federal Government
ClinicalTrials.gov processed this record on 2005-04-08